Vanda Pharmaceuticals (VNDA) Common Equity (2010 - 2026)

Vanda Pharmaceuticals has reported Common Equity for 17 years, with the latest figure at $280.8 million in Q1 2026.

• Quarterly Common Equity fell 45.1% year-over-year to $280.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $280.8 million (down 45.1% YoY) and the FY2025 annual result came in at $327.2 million, down 39.25% from the prior year.
• Common Equity declined to $280.8 million in Q1 2026 per VNDA's latest filing, from $327.2 million in the prior quarter.
• Over five years, Common Equity peaked at $544.9 million in Q4 2023 and troughed at $280.8 million in Q1 2026.
• A 5-year average of $497.4 million and a median of $527.2 million in 2022 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2026: Common Equity grew 7.38% in 2022, then tumbled 45.1% in 2026.
• Over 5 years, Common Equity stood at $527.2 million in 2022, then advanced by 3.36% to $544.9 million in 2023, then dropped by 1.17% to $538.5 million in 2024, then sank by 39.25% to $327.2 million in 2025, then dropped by 14.19% to $280.8 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $280.8 million, $327.2 million, and $466.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.